Abstract:BACKGROUND: The transient outward current (Ito) that mediates early (phase 1) repolarization is conducted by the KCND3 -encoded Kv4.3 pore-forming α-subunit. KCND3 gain-of-function mutations have been reported previously as a pathogenic substrate for J wave syndromes (JWS), including the Brugada syndrome and early repolarization syndrome, as well as autopsy-negative sudden unexplained death (SUD). Acacetin, a natural flavone, is a potent Ito current blocker. Acacetin may be a novel therapeutic for KCND3 -mediated J wave syndrome. METHODS: KCND3-V392I was identified in an 18-year-old male with J wave syndrome/early repolarization syndrome, and a history of cardiac arrest including ventricular tachycardia/ventricular fibrillation and atrial fibrillation/atrial flutter. Pathogenic KCND3 mutation was engineered by site-directed mutagenesis and co-expressed with wild-type KChIP2 in TSA201 cells. Gene-edited/variant-corrected isogenic control and patient-specific pluripotent stem cell–derived cardiomyocytes (iPSC-CMs) from the p. Val392Ile-KCND3-positive patient were generated. I to currents and action potentials were recorded before and after treatment with Acacetin using the whole cell patch-clamp and multielectrode array technique. Western blot and immunocytochemistry were performed to investigate KCND3 expression. RESULTS: KCND3-V392I demonstrated a marked gain-of-function phenotype, increasing peak I to current density by 92.2% ( P <0.05 versus KCND3-WT). KCND3 expression was significantly increased in KCND3-V392I-derived iPSC-CMs ( P <0.05 versus isogenic control). While KCND3-WT revealed an IC50 of 7.2±1.0 µmol/L for acacetin effect, 30 µmol/L acacetin dramatically inhibited KCND3-V392I peak Ito current density by 96.2% ( P <0.05 versus before Acacetin). Ito was also increased by 60.9% in Kv4.3-V392I iPSC-CM ( P <0.05 versus isogenic control iPSC-CM). Ten micromoles per liter acacetin, a concentration approaching its IC50 value, inhibited Ito by ≈50% in patient-derived iPSC-CMs and reduced the accentuated action potential notch displayed in KCND3-V392I-derived iPSC-CMs. CONCLUSIONS: This preclinical study provides pharmacological and functional evidence to suggest that Acacetin may be a novel therapeutic for patients with KCND3 gain-of-function-associated J wave syndrome by inhibiting I to and abolishing the accentuated action potential notch in patient-derived iPSC-CMs.

Abstract 12335: Acacetin, a Potent Transient Outward Current Blocker, May Serve As a Novel Therapeutic for KCND3-encoded Kv4.3 Gain-of-function-associated Brugada Syndrome

PO-615-05 ACACETIN, A POTENT TRANSIENT OUTWARD CURRENT BLOCKER, MAY BE A NOVEL THERAPEUTIC FOR KCND3-ENCODED KV4.3 GAIN-OF-FUNCTION-ASSOCIATED J-WAVE SYNDROMES

Acacetin, a Potent Transient Outward Current Blocker, May Be a Novel Therapeutic for <i>KCND3</i> -Encoded Kv4.3 Gain-of-Function-Associated

Acacetin, a Potent Transient Outward Current Blocker, May Be a Novel Therapeutic for KCND3-Encoded Kv4.3 Gain-of-Function-Associated J-Wave Syndromes.

Transient outward current (Ito) gain-of-function mutations in the KCND3-encoded Kv4.3 potassium channel and Brugada syndrome

KCNE2 Modulation of Kv4.3 Current and Its Potential Role in Fatal Rhythm Disorders

Properties and Molecular Determinants of the Natural Flavone Acacetin for Blocking Hkv4.3 Channels

Pharmacological Activation of Normal and Arrhythmia-Associated Mutant KCNQ1 Potassium Channels

Phase 2 Re-Entry Without Ito: Role of Sodium Channel Kinetics in Brugada Syndrome Arrhythmias.

KCNE2 Modulates the Function of Kv4.3 Channel

Supplementary Material For: A Novel Gain-of-Function KCND3 Variant Associated with Brugada Syndrome

Structure of KCNE1 and implications for how it modulates the KCNQ1 potassium channel.

Antisense Oligodeoxynucleotides Directed Against Kv1.5 Mrna Specifically Inhibit Ultrarapid Delayed Rectifier K + Current in Cultured Adult Human Atrial Myocytes

Modeling the Binding Modes of Kv1.5 Potassium Channel and Blockers.

Preparation, Functional Characterization, And Nmr Studies Of Human Kcne1, A Voltage-Gated Potassium Channel Accessory Subunit Associated With Deafness And Long Qt Syndrome

Novel Gain-of-Function Mutation in the Kv11.1 Channel Found in the Patient with Brugada Syndrome and Mild QTc Shortening

KCNE4-dependent modulation of Kv1.3 pharmacology

Building KCNQ1/KCNE1 Channel Models and Probing Their Interactions by Molecular-Dynamics Simulations.

Modulation of Human Cardiac Transient Outward Potassium Current by Egfr Tyrosine Kinase and Src-Family Kinases

Development of new Kir2.1 channel openers from propafenone analogues

The fully activated open state of KCNQ1 controls the cardiac 'fight-or-flight' response